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Abstract
Background: As with other alkylating agents, cardiac dysfunction can occur with tra-
bectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer 
(ROC) where treatment options for advanced disease are still limited. Cardiac safety 
for trabectedin monotherapy (T) for STS or in combination with pegylated liposomal 
doxorubicin (T+PLD) for ROC was evaluated in this retrospective postmarketing 
regulatory commitment.
Methods: Patient data for multiple cardiac- related treatment- emergent adverse events 
(cTEAEs) were evaluated in pooled analyses of ten phase 2 trials, one phase 3 trial in 
STS (n = 982), and two phase 3 trials in ROC (n = 1231).
Results: Multivariate analyses on pooled trabectedin data revealed that cardiovas-
cular medical history (risk ratio [RR (95% CI)]: 1.90 [1.24- 2.91]; p  =  0.003) and 
age ≥65 years (RR [95% CI]: 1.78 [1.12- 2.83]; p = 0.014) were associated with in-
creased risk for cTEAEs. Multivariate analyses showed increased risk of experiencing 
3566 |   JONES Et al.
1 |  INTRODUCTION
Trabectedin is a DNA- binding agent with a unique antitumor 
mechanism of action (MOA) targeting the transcription- coupled 
nucleotide excision repair (NER) system. Trabectedin was de-
veloped for the treatment of soft tissue sarcomas (STS) and 
epithelial ovarian cancer based on its novel cytotoxic activity. 
These cancers still have limited treatment options, particularly 
where advanced disease has progressed with other therapies.1
Preclinical studies with trabectedin showed no toxicity in 
cultured rat myocytes in vitro, while single and repeated doses 
in Cynomolgus monkeys did not induce any relevant cardiac, 
vascular, or respiratory effects.2 Further, a low incidence of 
cardiac- related treatment- emergent adverse events (cTEAE) 
was reported in previous analyses from earlier phase 1– 2 clin-
ical trials and one phase 3 (OVA- 301), pharmacovigilance 
databases, and spontaneously reported cases; tachycardia or 
palpitations were the most common cTEAEs reported.2 No 
clinically relevant left ventricular ejection fraction (LVEF) 
changes occurred in phase 1 combination trials, while LVEF 
decreases from baseline were similar [9% of patients (pe-
gylated liposomal doxorubicin [PLD]) and 7% (trabected-
in+PLD)] with no relevant symptoms in one phase 3 trial.2
Trabectedin is now approved for STS in 80 countries 
and for ovarian cancer in combination with PLD in 71 
countries. European Union (EU) approval for trabected-
in+PLD for relapsed platinum- sensitive ovarian cancer was 
granted in October 2009. In the United States (US), trabec-
tedin was approved for STS treatment following the fail-
ure of anthracycline- based chemotherapy in October 2015. 
Approval in the United States was contingent upon under-
taking post- marketing requirements to characterize risk of 
cardiotoxicity and its sequelae with trabectedin to identify 
risk factors including previous treatments known to be car-
diotoxic (e.g., anthracyclines).
As an extension to the cTEAE analysis reported in 20112, 
we now report the findings of this retrospective pooled anal-
ysis of key cTEAEs for all patients enrolled in ten phase 2 tri-
als and one phase 3 trial involving trabectedin monotherapy 
(T) for STS and other solid tumors and two phase 3 trials in 
combination with PLD for recurrent ovarian cancer (ROC).
2 |  METHODS
2.1 | Overall safety evaluation plan and 
description of safety studies
Safety analysis sets incorporated two pooled analyses: 
Cardiac safety with T was evaluated using data from ten 
phase 2 and one phase 3 trial (SAR- 3007 [NCT01343277]) in 
STS and other solid tumors at a dose and regimen of 1.5 mg/
m2 every 3 weeks (q3wk), 24 h. Cardiac safety with combi-
nation trabectedin+PLD was derived from two phase 3 ovar-
ian cancer trials (OVA- 301 [NCT00113607] and OVC- 3006 
[NCT01846611]) where trabectedin (1.1 mg/m2 q3wk; 3 h) 
was co- administered with PLD (30 mg/m2 q3wk; 90 min). 
Phase 3 trial designs are described in Table  1. Key inclu-
sion/exclusion criteria for enrollment are presented for each 
phase 3 trial (Table S1), cardiac safety evaluations by indi-
vidual trial (Table S2), and exposure and cancer diagnoses 
for pooled data from phase 2 and 3 studies (Table S3). Study 
protocols and amendments were reviewed by an Independent 
Ethics Committee or an Institutional Review Board.
2.2 | Statistical methodology
2.2.1 | Definition of subgroups and general 
analysis methods
Continuous variables were summarized using descriptive 
statistics (i.e., mean, standard deviation [SD], median, and 
range) and categorical variables by frequency counts and per-
centages. Time- to- event variable data were summarized by 
Kaplan- Meier methods for 25th, 50th, and 75th percentiles 
with 95% confidence intervals (CIs). Treatment group com-
parisons are presented by hazard ratios and 95% CI from Cox 
cTEAEs with T+PLD compared to PLD monotherapy (RR [95% CI]: 2.70 [1.75- 
4.17]; p < 0.0001) and with history of prior cardiac medication (RR [95% CI]: 1.88 
[1.16- 3.05]; p = 0.010).
Conclusions: For patients with STS or ROC who still have limited treatment options, 
trabectedin may be initiated after carefully considering benefit versus risk.
Trial Registration (ClinicalTrials.gov): NCT01343277; NCT00113607; NCT018 
46611.
K E Y W O R D S
anthracycline, cardiac toxicity, chemotherapy, patient outcomes, soft tissue sarcomas
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proportional hazards models. Anthracycline exposure data 
are summarized for subjects who received anthracyclines 
prior to the study (i.e., prior anthracycline) and for subjects 
who received anthracyclines prior to and during the study 
(i.e., cumulative anthracycline).
Two parameters were used for the cardiac safety analysis: 
LVEF significant decline where available and cardiac- related 
AEs of special interest (cardiac- related AEs). Cross tabula-
tion of ECG data were included when available.
2.2.2 | Cardiac- related adverse events
cTEAEs are summarized from time of first administration 
to 30  days after the last dose and graded using Common 
Terminology Criteria for Adverse Events (CTCAE; ver-
sion 4.0). Incidences of cTEAEs are defined by eight Medical 
Dictionary for Regulatory Activities (MedDRA) high- level 
group terms (HLGTs) and associated preferred terms (PTs) 
and two Standardized MedDRA Queries (narrow SMQ) 
(Table  2). HLGTs included cardiac and vascular investiga-
tions (excluding enzyme tests), cardiac arrhythmias, cardiac 
disorder signs and symptoms, coronary artery disorders, en-
docardial disorders, heart failures, myocardial disorders, and 
pericardial disorders. TEAEs were coded to MedDRA version 
16.0 for OVA- 301, SAR- 3007, and pooled safety analysis for 
T. TEAEs in OVA- 301 were aligned to MedDRA version 
19.0 to match the MedDRA version of OVC- 3006 and cTE-
AEs presented by HLGTs and SMQs and related PTs.
2.2.3 | Left ventricular ejection fraction
LVEF significant decline was defined as absolute decrease 
≥15%, or <lower limit of normal and absolute decrease ≥5%. 
LVEF recovery for subjects with significant LVEF decline 
T A B L E  1  Overview of study designs for phase 3 trials
Protocol Study description Treatment groups
Patients in safety 
analysis set, n
Phase 3 soft tissue sarcoma study – single- agent therapy
SAR- 3007 (NCT01343277) A multicenter, open- label, randomized, 
active- controlled, parallel- group phase 3 
study comparing the safety and efficacy 
of trabectedin versus dacarbazine 
among adults with unresectable, locally 
advanced or metastatic L- sarcoma, 
previously treated with at least an 
anthracycline and ifosfamide- containing 
regimen or an anthracycline- containing 
regimen and one additional cytotoxic 
chemotherapy regimen. A normal 
LVEF at baseline was not required for 
enrollment.
Trabectedin Arm: 1.5 mg/m2 as a 24 h 
IV infusion q3wk.
378
Dacarbazine Arm: 1 g/m2 as a 20- to 
120- min IV infusion q3wk.
172
Phase 3 ovarian cancer studies – combination therapy
OVA- 301 (NCT00113607) A multicenter, open- label, randomized 
study to assess the safety and efficacy 
of trabectedin+PLD versus PLD in 
patients with ROC treated with only one 
platinum- based chemotherapy regimen. 
Patients with a normal LVEF at baseline 
were eligible to enroll in the study.
Trabectedin+PLD Arm: PLD, 
30 mg/m2 as a 90- min infusion 
immediately followed by a 3 h 
trabectedin IV infusion 1.1 mg/m2 
q3wk.
333
PLD Arm: PLD, 50 mg/m2 as a 90- 
min infusion q4wk.
330
OVC- 3006 (NCT01846611) A multicenter, open- label, randomized 
study to assess the efficacy and 
safety of trabectedin+PLD as third 
line chemotherapy in patients with 
platinum- sensitive ROC who received 
two previous lines of platinum- based 
chemotherapy. Patients with a normal 
LVEF at baseline were eligible to enroll 
in the study.
Treatment Arm A: PLD 30 mg/m2 as 
a 90- min infusion immediately 
followed by a 3 h trabectedin 
infusion 1.1 mg/m2 q3wk.
286
Treatment Arm B: PLD, 50 mg/m2 as 
a 90- min infusion q4wk.
282
Abbreviations: IV, intravenous; L- sarcoma, leiomyosarcoma or liposarcoma; LVEF, left ventricular ejection fraction; PLD, pegylated liposomal doxorubicin; q3wk, 
once every 3 weeks; q4wk, once every 4 weeks; ROC, recurrent ovarian cancer.
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was defined as either return to baseline values or <Grade 
2 ejection fraction decreased toxicity (CTCAE v4.0). In 
all three phase 3 studies (SAR- 3007, OVA- 301, and OVC- 
3006), LVEF assessments were performed at baseline and 
end of treatment. Additionally, OVC- 3006 was amended to 
provide comprehensive cardiac evaluations of patients while 
on treatment. Collection time points for LVEF in each study 
are described in Table S2.
3 |  RESULTS
3.1 | Overall exposure
Table  3 shows the number of patients exposed to study 
drug by individual trial and by pooled safety analysis sets 
for T and trabectedin+PLD. Nine hundred and eighty- two 
patients were exposed to T, and 619 patients were treated 
with trabectedin+PLD.
3.2 | Baseline characteristics: trabectedin 
monotherapy (T)
3.2.1 | Demographic characteristics
Patients treated with trabectedin (N = 982) had a median 
(range) age of 54 (12– 81) years (Table S4). Most pa-
tients were female (61.6%), white (50.6%), from North 
America (58.2%) or Western Europe (36.7%), had an 
Eastern Cooperative Oncology Group performance score 
of 0 or 1 (99.8%), and a diagnosis of STS (88.0%). Prior 
anthracycline use was reported for 71.3% (Table  4). 
Prior anthracycline dose was only captured in the phase 
3 SAR- 3007 study. A cumulative dose of prior anthracy-
cline was reported for 337/378 subjects in the trabectedin 
treatment group and 162/172 subjects in the dacarbazine 
group. Median cumulative prior anthracycline dose was 
270.00 mg/m2 in the trabectedin group and 240.75 mg/m2 
in the dacarbazine group.
3.2.2 | Cardiovascular medical history
Pooled analyses of T, cardiovascular medical history cate-
gorized under the vascular disorder and/or cardiac disorder 
system organ class (SOC) was reported for 355 (36.2%) of 
982 trabectedin- treated patients. The most commonly re-
ported cardiovascular medical history for patients treated 
with trabectedin were hypertension (24.8% [244/982]), 
followed by deep vein thrombosis (2.9% [28/982]), hot 
flush (2.2% [22/982]), and coronary artery disease (2.1% 
[21/982]).
cTEAEs
HLGT Cardiac and vascular investigations (excluding enzyme tests)
Cardiac arrhythmias








Abbreviations: cTEAEs, cardiac- related treatment- emergent adverse events; HLGT, high- level group term; 
MedDRA, Medical Dictionary for Regulatory Activities; SMQ, standardized MedDRA query.
T A B L E  2  MedDRA HLGT and 
standardized MedDRA queries (narrow 
SMQ)
T A B L E  3  Number of patients exposed to study treatment and 
safety analysis sets
Study No. patients in safety analysis set
Monotherapy Trabectedin Dacarbazine
SAR- 3007 378 172
10 phase 2 Studies 604 – 




Combination Therapy Trabectedin+PLD PLD
OVA- 301 333 330
OVC- 3006 286 282
Pooled Data (OVA- 
301+OVC- 3006)
619 612
Abbreviation: PLD, pegylated liposomal doxorubicin.
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3.3 | Baseline characteristics: trabectedin in 
combination with PLD
3.3.1 | Demographic characteristics
In the pooled analysis of trabectedin+PLD, patient de-
mographic characteristics were consistent in the all- 
female study populations across the trabectedin+PLD 
(N = 619) and PLD monotherapy (N = 612) groups, with 
median (range) ages of 58 (26– 83) and 59 (27– 91) years, 
respectively. Most patients were white (84% and 82%, 
respectively) (Table S5), and baseline disease charac-
teristics were consistent across both treatment groups 
(Table 5).
3.3.2 | Cardiovascular medical history
In pooled analysis of trabectedin+PLD, 45.6% and 51.5% 
of patients in the trabectedin+PLD and PLD monotherapy 
groups, respectively, had prior cardiovascular medical his-
tory reported for vascular and/or cardiac disorders SOC. 
These included: hypertension (30.5% [189/619] in the 
trabectedin+PLD group and 34.6% [212/612] in the PLD 
monotherapy group), followed by myocardial ischemia 
(6.0% [37/619] and 6.7% [41/612], respectively), varicose 
vein (3.9% [24/619] and 3.8% [23/612], respectively), deep 
vein thrombosis (2.7% [17/619] and 2.5% [15/612], respec-
tively), and hot flush (1.8% [11/619] and 2.9% [18/612], 
respectively).
3.4 | Cardiac safety results
3.4.1 | Trabectedin monotherapy (T)
In the pooled analysis of T, 110 (11.2%) patients who re-
ceived ≥1 trabectedin dose experienced a cTEAE (Table S6). 
cTEAEs reported for ≥1% of trabectedin- treated patients 
included tachycardia (3.1%), palpitations (1.5%), LVEF 
decrease (1.3%), sinus tachycardia (1.0%), and congestive 
cardiac failure (1.0%). Median time from the first dose of 
study drug to the onset of first occurrence of a cTEAE for 
trabectedin- treated patients was 40  days. For 65% of pa-
tients with cTEAE, the event was reported as resolved, with 
a median time to resolution of 8 days. Thirty- seven (3.8%) 
trabectedin- treated patients experienced a Grade 3 or 4 
cTEAE (Table S7). Cardiac- related serious TEAEs (SAEs) 
were reported in 36 (3.7%) trabectedin- treated patients (Table 
S8); those most frequently reported (≥5 patients) included: 
congestive cardiac failure (0.8%), pulmonary edema (0.6%), 
ejection fraction decreased (0.5%), cardiac failure (0.5%), 
T A B L E  4  Disease characteristics for patients treated with 








STS, L- type 661 (67.3)






Prior anthracycline treatment 700 (71.3)
Data are presented as No. (%).
Abbreviations: L- type, leiomyosarcoma or liposarcoma; STS, soft tissue 
sarcomas; q3wk, once every 3 weeks.
T A B L E  5  Disease characteristics at baseline for treated patients 





Papillary/Serous 412 (66.6) 420 (68.6)
Other 97 (15.7) 92 (15.0)
Endometrioid 38 (6.1) 37 (6.0)
Clear Cell 
Carcinoma
24 (3.9) 21 (3.4)
Peritoneal 
Carcinoma
21 (3.4) 17 (2.8)
Fallopian Tube 
Carcinoma
10 (1.6) 15 (2.5)
Mixed Epithelial 
Tumor
7 (1.1) 5 (0.8)
Mucinous 
(exclusion)




5 (0.8) 2 (0.3)
Prior anthracycline 
treatment
38 (6.1) 36 (5.9)





24.25 (6.6, 169.3) 25.17 (2.5, 230.4)
Data are presented as No. (%) unless otherwise specified.
Abbreviation: PLD, pegylated liposomal doxorubicin.
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and atrial fibrillation (0.5%). Six (0.6%) trabectedin- treated 
patients experienced a cTEAE leading to death (Table S9).
3.4.2 | Unique study features
In the phase 3 study comparing trabectedin versus dacar-
bazine (SAR- 3007), cTEAEs were reported for 58 (15.3%) 
trabectedin patients and 25 (14.5%) dacarbazine patients; 
however, cardiac failure (5.0% vs. 2.3%), cardiomyopa-
thy (3.7% vs. 2.3%), and heart failure (2.9% vs. 0.6%) were 
higher with trabectedin. Furthermore, the median cumula-
tive prior anthracycline dose was greater in the trabectedin 
group (329.75  mg/m2) compared to the dacarbazine group 
(180.00 mg/m2), which should also be taken into considera-
tion. Among patients with a cTEAE, more patients in the 
trabectedin group (39 [67.2%] of 58) received a prior cumu-
lative anthracycline dose ≥300  mg/m2 compared with the 
dacarbazine group (10 [40.0%] of 25). Median time from the 
first dose of study drug to the onset of first occurrence of a 
cTEAE was twice as long in the trabectedin group compared 
with the dacarbazine group (46 days vs. 23 days); however, 
the median time to resolution was twice as long in the trabect-
edin group (8 days vs. 4 days). In terms of prior anthracycline 
exposure among patients with a significant decrease in LVEF 
from baseline and for whom dose information was reported, 
prior cumulative anthracycline dose of ≥300 mg/m2 was re-
ported in 22/34 (64.7%) in the trabectedin group compared 
with 7/11 (63.6%) patients in the dacarbazine group.
3.4.3 | Trabectedin in combination with PLD
cTEAEs were reported for 78 (12.6%) patients in the 
trabectedin+PLD group and 34 (5.6%) patients in the PLD 
monotherapy group; most commonly reported cTEAE was 
LVEF decrease (7.8% vs. 4.2%, respectively). Within these 
SMQ/HLGTs, palpitation was the only cTEAE reported with 
at least a 2% greater incidence in the trabectedin+PLD group 
compared with the PLD monotherapy group (3.2% vs. 1.0%) 
(Table S10).
Kaplan- Meier analyses showed an increased risk of cTE-
AEs with trabectedin+PLD compared with PLD monother-
apy (Figure  1). Cumulative incident rate curves separated 
early and remained separated throughout treatment. Median 
time from first study dose to the onset of first occurrence of 
cTEAE was shorter with trabectedin+PLD (57  days) com-
pared with PLD monotherapy (98 days), while most patients 
in both groups had similar resolutions of cTEAEs (57.1% and 
55.9%) and time to resolution (8 days). However, while Grade 
3 or 4 cardiac- related events were reported more frequently 
with trabectedin+PLD versus PLD monotherapy (14 [2.3%] 
vs. 4 [0.7%] patients; Table S11); no cTEAEs were reported 
with an incidence of ≥1% in either group. Last, cardiac- 
related SAEs were reported more frequently with trabected-
in+PLD (11 [1.8%]) vs. PLD monotherapy (3 [0.5%]) (Table 
S12). Congestive heart failure was quite low in both the com-
bination (3 [0.5%]) and monotherapy groups (1 [0.2%]).
3.4.4 | Unique study features
In OVA- 301, fewer patients with a significant decrease 
from baseline in LVEF in the trabectedin+PLD group had 
a cardiovascular medical history compared with the PLD 
monotherapy group (23.8% vs. 52.6%). In OVC- 3006, me-
dian cumulative PLD dose for patients with a cTEAE was 
lower with trabectedin+PLD treatment compared with PLD 
monotherapy (180.78 vs. 329.67  mg/m2). Median cumula-
tive anthracycline dose of ≥300 mg/m2 was reported in 11/43 
F I G U R E  1  Cumulative Incidence 
of Cardiac- Related Adverse Events Over 
Treatment Duration for Treated Patients 
(Pooled Studies ET743- OVC- 3006 and 
ET743- OVA- 301). PLD, pegylated 
liposomal doxorubicin
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(25.6%) in trabectedin+PLD patients with a cTEAE com-
pared to 17/23 (73.9%) PLD monotherapy patients.
In OVC- 3006, the median time from first dose of drug to 
the onset of first occurrence of a cTEAE was shorter with 
trabectedin+PLD compared with PLD monotherapy (68 days 
vs. 169  days); however, the median time to resolution was 
longer with PLD monotherapy group compared with trabec-
tedin+PLD (29 days vs. 16 days). Median cumulative PLD 
dose for patients having significant decreases from baseline 
in LVEF was lower in the trabectedin+PLD group compared 
with the PLD monotherapy group (149.39 vs. 251.25  mg/
m2). In addition, median cumulative anthracycline doses of 
≥300  mg/m2 were associated with a significant decrease 
from baseline in LVEF; this was reported in 3/19 (15.8%) tra-
bectedin+PLD and 5/10 (50.0%) PLD monotherapy patients.
3.5 | Multivariate analyses
3.5.1 | Trabectedin monotherapy
Trabectedin- treated patients who experienced a cTEAE 
were generally older (18.4% aged ≥65 years vs. 9.6% aged 
<65 years). Results from multivariate analyses of cTEAEs 
when controlling for potential risk factors are presented in 
Figure  2. These showed that patients aged ≥65  years and 
those with cardiovascular medical history had an increased 
risk of cTEAEs. The effect of cumulative anthracycline dose 
of ≥300 versus <300  mg/m2 and baseline LVEF <lower 
limit of normal (LLN) versus ≥LLN, however, could not 
be evaluated in the ten phase 2 studies due to differences in 
study designs.
3.5.2 | Trabectedin in combination with PLD
In the multivariate analyses, when controlling for poten-
tial risk factors, results showed that patients receiving 
trabectedin+PLD were at increased risk for experiencing a 
cTEAE compared with PLD monotherapy (risk ratio [RR] 
2.70; 95% CI: 1.75– 4.17; p  <  0.0001). Furthermore, pa-
tients with a history of prior cardiac medication use who re-
ceived trabectedin+PLD versus PLD were also at increased 
risk of experiencing cTEAEs (RR 1.88; 95% CI: 1.16– 3.05; 
p = 0.010). Patients with a cumulative anthracycline dose of 
≥300  mg/m2 who received trabectedin+PLD in the OVC- 
3006 and OVA- 301 trials were at increased risk for a signifi-
cant decrease in LVEF compared with patients who received 
PLD monotherapy (RR 0.54; 95% CI: 0.30– 0.99; p = 0.046) 
(Figure 3).
F I G U R E  2  Multivariate Analysis on Incidence of Cardiac- Related TEAEs (Logistic Regression) for Treated Patients (Trabectedin – Pooled 
Phase 2 and 3 Studies). Dependent variable: incidence of cardiac- related TEAEs. CI, confidence interval; TEAEs, treatment- emergent adverse 
events
F I G U R E  3  Multivariate Analysis on 
Incidence of Significant LVEF Decrease 
(Logistic Regression) for Treated Patients 
(Pooled Studies OVC- 3006 and OVA- 301). 
Dependent variable: incidence of significant 
LVEF decrease. CI, confidence interval; 
LVEF, left ventricular ejection fraction; 
PLD, pegylated liposomal doxorubicin
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4 |  DISCUSSION
Trabectedin was developed based on its novel chemical 
structure and promising preclinical activity in several types 
of human tumors. The development program focused on 
STS3 and ROC4,5 in which trabectedin was active at very 
low concentrations in both preclinical models and clinical 
trials.1 Trabectedin binds to the N2 position of guanine 
in the minor groove of DNA and bends the helix toward 
the major groove, a unique property in the class of DNA- 
binding agents; it triggers a cascade of events affecting 
several transcription factors, DNA- binding proteins, and 
DNA- repair pathways (e.g., transcription- coupled NER), 
resulting in slowed progression through S and G2/M phases 
and p53- independent apoptosis. Trabectedin also prevents 
the binding of translocation- related oncogenic fusion pro-
teins to DNA promoter regions, thereby interfering with 
the function of proteins that contribute to the malignant 
phenotype and tumor progression.6– 9
PLD is doxorubicin hydrochloride encapsulated in 
STEALTH® liposomes for intravenous administration. PLD 
was granted approvals for advanced ovarian cancer in June 
1999 and October 2000 in the United States and European 
Union, respectively. As with any anthracycline, PLD can 
cause myocardial damage, including congestive heart failure, 
as the total cumulative dose of doxorubicin hydrochloride ap-
proaches 550 mg/m2. In a clinical study of 250 patients with 
advanced cancer who were treated with PLD, the risk of car-
diotoxicity was 11% when the cumulative anthracycline dose 
was 450 to 550 mg/m2.10
This is the most comprehensive analysis of cardiac safety 
in the setting of trabectedin administration from clinical trial 
data including more than 1600 patients. Strengths include 
pooled analyses of one phase 3 trial and ten phase 2 trials of 
T in STS and two phase 3 trials of trabectedin in combination 
with PLD for ROC. Limitations include patient heterogene-
ity and varying dosing, scheduling, and infusion times for T 
(1.5  mg/m2 q3wk; 24  h) compared with PLD combination 
therapy (trabectedin 1.1 mg/m2 q3wk; 3 h). The authors rec-
ognize that cardiac adverse events with diverse etiologies 
make it difficult to ascribe the outcomes to trabectedin alone 
or identify specific causal mechanisms. Cardiotoxicity may 
be mediated by multiple mechanisms including damage from 
prior cardiotoxic therapies (anthracyclines), preexisting car-
diovascular comorbidities, and the alkylating MOA among 
others. Last, the retrospective nature of data collection and 
other events, such as sepsis (that could contribute to cardiac 
events) are additional limitations.
In phase 3 SAR- 3007 study3, no difference in the overall 
incidence rate of any- grade cTEAEs was observed between 
trabectedin- and dacarbazine- treated patients. Multivariate 
analysis of safety data (data not shown) indicated that cumu-
lative anthracycline dose of ≥300 mg/m2 and baseline LVEF 
<LLN were risk factors for the development of cTEAEs in 
STS. In pooled analyses, only age ≥65 years and cardiovas-
cular medical history were associated with an increased risk 
of cTEAEs. This difference could be attributed to variability 
in patient populations, pretreatment history, and consistent 
baseline LVEF testing in the ten phase 2 studies compared 
with SAR- 3007. In summation, cardiac safety signals ob-
served with T may be, in part, due to the history of prior or 
concurrent therapy with an anthracycline, known for poten-
tial short- and long- term cardiotoxicity, and longer median 
duration of treatment for patients receiving trabectedin.
In OVA- 301 and OVC- 3006, patients in the trabected-
in+PLD groups experienced cTEAEs at a higher incidence, 
regardless of toxicity grade, compared with PLD monother-
apy patients. In OVA- 301, multivariate analyses indicated an 
increased risk of cTEAEs among patients in the trabected-
in+PLD group compared with PLD monotherapy (data not 
shown). In OVC- 3006, however, a cumulative anthracycline 
dose of ≥300 mg/m2 and prior cardiac medication use were 
also identified as independently associated with increased 
risk of cTEAEs (data not shown). Differences between the 
two studies may be attributed to enrollment criteria for each 
study. Inclusion criteria for OVC- 3006 differed from OVA- 
301 in that patients were allowed to have received two prior 
lines versus one  line of chemotherapy for ROC, and prior 
PLD combination therapy was also allowed.
Ultimately, these data suggest that some patients re-
ceiving T after prior therapy with anthracyclines are at risk 
for cTEAEs, which may be serious in a small number. The 
overall risk of fatal events is relatively low but appears to be 
higher for patients with existing myocardial dysfunction (ab-
normal LVEF) or prior cardiovascular medical history. In the 
setting of STS, the available data support recommendations 
to assess LVEF by echocardiogram or multigated acquisition 
radionuclide scan before the initiation of trabectedin and at 
two- to three- month intervals thereafter until trabectedin is 
discontinued, particularly for patients with prior cardiovas-
cular disease. Additionally, when using trabectedin in com-
bination with PLD for ROC, cumulative anthracycline dose 
≥300 mg/m2 and prior cardiac medication may increase the 
risk of cTEAEs if prior lines of therapy involved PLD.
In conclusion, as with any systemic cytotoxic therapy, 
benefit versus risk should be carefully considered when in-
stituting treatment with trabectedin in patients with few other 
treatment options and with risk factors for developing cTE-
AEs. In consultation with a cardiologist or cardio- oncology 
service, baseline cardiovascular risk should be comprehen-
sively assessed before commencing treatments with car-
diotoxic potential as noted above.11,12 Cardiotoxicity risk 
can be minimized by primary prevention strategies; signs 
and symptoms of myocardial toxicity including decreases 
in LVEF should be assessed routinely as described above. 
Dose reductions or temporary or permanent discontinuation 
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of trabectedin should be considered when serious cTEAEs 
occur. Once the decision is made that benefits of trabectedin 
therapy outweigh risk, patients (and caregivers) should be 
supported throughout treatment with a personalized surveil-
lance program to minimize cTEAE risk and promptly address 
when cTEAEs do occur.
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